WASHINGTON, Feb 17 (Reuters) - U.S. health regulators are reviewing potential risks of medicines from Roche Holding AG , Novartis AG and other companies.
The Food and Drug Administration said on Wednesday it was probing reports of hearing loss with Novartis cancer drug Gleevec, hypothermia with Roche's flu drug Tamiflu and pericarditis with Biogen Idec and Elan Corp's multiple sclerosis drug Tysabri.
The FDA releases a quarterly list of safety probes as part of an effort to inform the public about early investigations of potential side effects that have been reported. The lists released on Wednesday cover issues identified between April 2009 and September 2009.
Appearing on the list 'does not mean that FDA has identified a causal relationship between the drug and the listed risk,' the FDA said.
(Reporting by Lisa Richwine; Editing by Tim Dobbyn) Keywords: FDA DRUGS/ (lisa.richwine@thomsonreuters.com; + 1 202 310 5691; www.twitter.com/ReutersLisaRx) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The Food and Drug Administration said on Wednesday it was probing reports of hearing loss with Novartis cancer drug Gleevec, hypothermia with Roche's flu drug Tamiflu and pericarditis with Biogen Idec and Elan Corp's multiple sclerosis drug Tysabri.
The FDA releases a quarterly list of safety probes as part of an effort to inform the public about early investigations of potential side effects that have been reported. The lists released on Wednesday cover issues identified between April 2009 and September 2009.
Appearing on the list 'does not mean that FDA has identified a causal relationship between the drug and the listed risk,' the FDA said.
(Reporting by Lisa Richwine; Editing by Tim Dobbyn) Keywords: FDA DRUGS/ (lisa.richwine@thomsonreuters.com; + 1 202 310 5691; www.twitter.com/ReutersLisaRx) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.